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the overall cost (€884) was not ﬁnanced by Social Security, and
the majority of this cost corresponded to caregiver associated
cost (salaries and productivity lost). The caregiver economical
burden represents 68% of the overall cost-of-illness. CONCLU-
SIONS: Monthly overall mean cost of AD was high in Spain
(€1078), More than 80% of the cost-of-illness is funded by the
own patient family, adding an economical burden to the suffer-
ing of these families.
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OBJECTIVES: International studies have reported that patients
with ADHD incur higher health care costs than persons without
this condition, but little is known about the direct medical costs
associated with ADHD in Germany. The present study aims at
ﬁlling this void. METHODS: Health care resource utilization
data for patients with a diagnosis of ADHD (F90.0 and/or F90.1)
were extracted from the Nordbaden claims database (for year
2003), covering the complete regional population insured by
Statutory Health Insurance SHI (2.238 million lives in 2003),
and were combined with SHI prescription data. Complete
datasets were available for 3,831 outpatients with ADHD and
for a randomly selected control group matched 1:1 by age and
gender. For costing, resource use was valued applying SHI acqui-
sition costs. RESULTS: The annual average expenditure (direct
medical costs borne by SHI) per patient was €650 versus €251 for
matched controls, with physician charges accounting for 68%
(€444 versus €170 for controls). All categories of costs were
higher for patients with ADHD by a factor of 2 to 5 versus
controls, an observation that was consistent across age and
gender deﬁned subgroups. Average expenditures per patient with
ADHD increased with age (age group <7 years, €520; 7–12 years,
€622; 13–19 years, €661; >20 years, €1147), primarily reﬂecting
higher medication costs. In contrast, average costs per control
person showed little change across age groups (at €269, €245,
€250, and €272, respectively). Among children and adolescents,
there were no substantial spending differences by gender. CON-
CLUSIONS: These data are likely underestimates of the total
expenditures attributable to ADHD since they do neither include
costs of inpatient treatment nor cost of ergotherapeutic interven-
tions, which will have to be addressed in future studies. They
provide, for the ﬁrst time, robust information from Germany on
the signiﬁcant ﬁnancial burden for the SHI attributable to
ADHD.
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The type of antipsychotic determines the efﬁcacy and the toler-
ability for the patient. Long acting depot formulations were
designed to increase patient adherence to treatment. The second
generation atypical antipsychotics and long-acting injectable ris-
peridone (LAIR) in particular are more costly than conventional
antipsychotics, but may improve outcome of treatment; hence,
reducing costs associated with schizophrenia. OBJECTIVES:
Firstly, to provide estimates of the economic impact of schizo-
phrenia in Germany and to illustrate the cost-drivers in the
disease. Secondly, to present ﬁndings from a literature search of
published cost-effectiveness analyses of second generation schizo-
phrenia treatment, with focus on depot treatment. METHODS:
Based on data from the German Federal Bureau of Statistics,
the costs of schizophrenia were estimated from a top-down
approach. Additionally, costs were illustrated from a bottom-up
prevalence approach, based on data from published literature. A
literature search, using PubMed, was conducted to ﬁnd cost-
effectiveness data. RESULTS: Using a top-down approach, total
cost of schizophrenia in Germany was estimated to €7298
million in 2004. Direct and indirect costs were estimated to
€2715 and €4583 million respectively. Hospital stays represented
the largest share of the direct costs while invalidity was the main
reason for indirect costs. From the bottom-up approach, the total
cost of schizophrenia was estimated to between €4,920 million
and €10,420 million per year. The review of available economic
models shows that LAIR has a substantial cost advantage and
has been demonstrated to be cost- effective compared to alterna-
tive treatments. CONCLUSIONS: Schizophrenia is associated
with high health care and societal costs. LAIR has the potential
to improving the outcome of treatment, e.g. compliance; hence,
lower the costs associated with schizophrenia. Longer trials in a
naturalistic setting and studies regarding patient satisfaction of
LAIR are however requested.
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OBJECTIVES: While the substantial economic burden of depres-
sion is well documented, less is known about the cost of depres-
sion by clinical severity levels. This study’s objective is to
document the health care resource utilization and costs by sever-
ity for patients with major depressive disorder (MDD).
METHODS: Using data from the National Comorbidity Survey-
Replication (NCS-R; n = 5692), respondents were categorized
into clinical severity categories (not clinically depressed, mild,
moderate, severe) using standard scales (CIDI/QIDS-SR). Out-
comes were measured over 12 months and included the preva-
lence of medical services and antidepressant use, the average
number of visits and days on antidepressants, the prevalence of
treatment adequacy, and medical and drug costs. Costs were
estimated by weighting utilization measures by unit costs
obtained for similar services used by depressed patients in a U.S.
privately insured claims database for the corresponding time
period (2000–2001). Outcomes were compared across depres-
sion severity groups using chi-square tests and regression models
that generated F statistics adjusted for demographics. RESULTS:
Among the 658 depressed respondents, 14.2% were mildly,
38.1% moderately and 47.7% severely depressed. Respondents
in the 3 groups shared similar demographic characteristics. There
was a signiﬁcant association between severity and the prevalence
of mental health services usage (20.8%, 27.9%, and 39.5%
respectively, p < 0.01) and the average number of mental health
practitioner visits. The use of antidepressants also increased with
depression severity (19.8%, 29.8%, and 40.2% respectively, p <
0.05). Similarly, the adequacy of mental health services increased
with depression severity (8.9%, 12.1%, and 21.3% respectively,
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